Department of Biology, Islamic Azad University of Tonekabon Branch, Tonekabon, Iran.
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Life Sci. 2020 Jan 1;240:117077. doi: 10.1016/j.lfs.2019.117077. Epub 2019 Nov 18.
Importance of dysregulation and expression of microRNAs (miRNAs) has been confiemed in many disorders comprising cancer. In this way, different approaches to induce reprogramming from one cell type to another in oerder to control the cell normal mechanisem, comprising microRNAs, combinatorial small molecules, exosome-mediated reprogramming, embryonic microenvironment and also lineage-specific transcription agents, are involved in cell situation. Meaningly, besides the above factors, microRNAs are so special and have an impressive role in cell reprogramming. One of the main applications of cancer cell reprogramming is it's ability in therapeutic approach. Many insights in reprogramming mechanism have been recommended, and determining improvment has been aknolwged to develop reprogramming efficiency and possibility, permiting it to appear as practical therapy against all cancers. Conspiciously, the recent studies on the fluctuations and performance of microRNAs,small endogenous non-coding RNAs, as notable factors in carcinogenesis and tumorigenesis, therapy resistance and metastasis and as new non-invasive cancer biomarkers has a remarkable attention. This is due to their unique dysregulated signatures throughout tumor progression. Recognising miRNAs signatures capable of anticipating therapy response and metastatic onset in cancers might enhance diagnosis and therapy. According to the growing reports on miRNAs as novel non-invasive biomarkers in various cancers as a main regulators of cancers drug resistance or metastasis, the quest on whether some miRNAs have the ability to regulate both simultaneously is inevitable, yet understudied. The combination of genetic diagnosis using next generation sequencing and targeted therapy may contribute to the effective precision medicine for cancer therapy. Here, we want to review the practical application of microRNAs performance in carcinogenesis and tumorigenesis in cancer therapy.
重要的是,miRNAs(microRNAs)的失调和表达已在许多疾病中得到证实,包括癌症。在这种情况下,涉及到不同的方法来诱导一种细胞类型向另一种细胞类型的重编程,以控制细胞的正常机制,包括 microRNAs、组合小分子、外泌体介导的重编程、胚胎微环境以及谱系特异性转录因子等。值得注意的是,除了上述因素外,microRNAs 非常特殊,在细胞重编程中发挥着重要作用。癌症细胞重编程的主要应用之一是其在治疗方法中的能力。已经提出了许多关于重编程机制的见解,并且确定了改善重编程效率和可能性的方法,使得它可以作为针对所有癌症的实际治疗方法出现。值得注意的是,最近对 microRNAs(小内源非编码 RNA)的波动和表现的研究,作为致癌作用和肿瘤发生、治疗耐药性和转移的显著因素,以及作为新的非侵入性癌症生物标志物,引起了人们的关注。这是由于它们在肿瘤进展过程中独特的失调特征。识别能够预测癌症治疗反应和转移发生的 miRNAs 特征可能会增强诊断和治疗。鉴于越来越多的关于 microRNAs 作为各种癌症中新型非侵入性生物标志物的报道,作为癌症药物耐药性或转移的主要调节剂,一些 microRNAs 是否同时具有调节两者的能力是不可避免的,但研究较少。使用下一代测序进行遗传诊断和靶向治疗的结合可能有助于癌症治疗的有效精准医学。在这里,我们想回顾一下 microRNAs 在癌症治疗中的致癌作用和肿瘤发生中的实际应用。